Cisplatin secondary malignancy

Author: fjhy

August undefined, 2024

WebDec 19, 2024 · Second cancers were reported in 143 patients, including 75 patients in the cisplatin arm and 68 in the non-cisplatin arm (raw event rates of 1.91 and 1.96%, respectively). The pooled OR for risk of all second cancers associated with cisplatin … WebTreatment of lung cancer, the most common type of carcinoma, is difficult due to disease progression at the time of diagnosis, causing a high mortality rate. 1, 32 Cisplatin (DDP), also known as cis-diaminodichloplatin, is a powerful nonspecific drug blocking the cell cycle. 33, 34 DDP can enter cells through the passive transport.

Cisplatin Cancer information Cancer Research UK

WebDec 1, 2024 · Methods. In this open-label, randomized, phase III study, newly diagnosed patients with advanced NSCLC were initially randomized (R1, 1:1) to receive first-line treatment with cisplatin 75 mg/m 2 plus docetaxel 75 mg/m 2 (DC75) or 60 mg/m 2 (DC60) for up to 4 cycles. Patients without progression were further randomized (R2, 1:2) to best … WebMar 2, 2024 · Cisplatin and carboplatin are among the most important drugs introduced during the past three decades for the treatment of … portheine

Persistence of cisplatin-induced mutagenicity in hematopoietic …

WebDec 19, 2024 · Background Case reports, retrospective analyses, and observational studies have linked the use of cisplatin to increased risk of second cancers, especially life-threatening secondary leukemia. We therefore performed a systematic review and meta-analysis to evaluate the risk of second cancers associated with receipt of cisplatin … WebFeb 1, 2013 · What are secondary malignancies? A secondary malignancy is a new cancer that occurs in an individual as a result of previous treatment with radiation or … WebApr 11, 2024 · Additionally, the Company has rights in two secondary assets: 2X-111, a liposomal formulation of doxorubicin for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject ... opti cover wifi extender setup

Cisplatin secondary malignancy

Risk of Leukemia after Platinum-Based Chemotherapy for …

WebFeb 16, 2024 · Common side effects of cisplatin may include: hearing problems; kidney problems; numbness or tingling; nausea, vomiting; or. bone marrow suppression. This is … Webchemotherapy in the adjuvant treatment of high -risk breast cancer, and with high dose–intensity methotrexate, vinblastine, doxorubicin, and cisplatin (HD-M-VAC) in urothelial cancer. There are limited and conflicting data on the value of dose-dense regimens with CSF support in non-Hodgkin lymphoma (NHL), and it cannot routinely be …

Did you know?

WebSecondary actions. Search Journals Articles Documentation API OAI-PMH Widgets ... Integrin α6β4 signals through DNA damage response pathway to sensitize breast cancer cells to cisplatin Min Chen, Min Chen, Brock Marrs, Lei Qi, Teresa Knifley, Heidi L. Weiss, Heidi L. Weiss, John A. D’Orazio, John A. D’Orazio, ... WebSecondary malignancies are cancers caused by treatment with radiation or chemotherapy. They are unrelated to the first cancer that was treated, and may occur months or even …

WebSep 15, 2024 · Cisplatin is mutagenic, teratogenic and carcinogenic and its use has been show to increase the risk of secondary malignancies, particularly leukemia. … WebApr 15, 2024 · Based on medical history and clinical manifestations, the solid space-occupying lesion in the left atrium was suspected to be cardiac metastases from bladder cancer despite treatment with pirarubicin, gemcitabine and cisplatin.

WebFeb 27, 2024 · The prognosis of patients with recurrent or metastatic head and neck squamous cell cancer is generally poor. The median survival in most series is 6 to 15 months depending on patient- and disease-related factors. Symptom-directed care plays an important role in the management of these patients. Web2.3 Advanced Ovarian Cancer . Cisplatin for injection has been administered at 75 mg/m. 2 . to 100 mg/m. intravenously per cycle once every 3 to 4 weeks on Day 1. Other doses …

WebCisplatin is a type of chemotherapy. It destroys quickly dividing cells, such as cancer cells. Find out more about how chemotherapy works How do you have cisplatin? You have …

WebNational Center for Biotechnology Information porthelper 下载WebA quick look at the research seems to show cisplatin is less risky than carboplatin in terms of secondary cancer (like leukemia). A study on women who were treated with platinum … porthellisWebDec 19, 2024 · Second cancers were reported in 143 patients, including 75 patients in the cisplatin arm and 68 in the non-cisplatin arm (raw event rates of 1.91 and 1.96%, … opti easy fold treadmill manualWebJun 1, 2024 · tion with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol 2015;16:967-978. DOI: 10.1016/S1470-2045(15)00139-4 . 3. Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, porthello cove golf clashWebMar 15, 2024 · FIRST-LINE THERAPY — A cisplatin-based combination chemotherapy regimen is the preferred initial therapy for patients with metastatic urothelial cancer of … opti crystalWebAug 1, 2014 · Cisplatin is a cytostatic agent used in the treatment of many types of cancer, but its use is associated with increased incidences of secondary leukemia. … porthejsWebplatinum-based drugs, such as cisplatin, oxaliplatin and carboplatin . taxanes such as docetaxel and paclitaxel thalidomide interferon alpha (Rofeon-A ® ). You may be at a higher risk if you: are having more than one type of drug or treatment that can cause nerve damage have had anti-cancer drugs in the past that can cause peripheral neuropathy porthelle portas